ARA-290 for Nerve Damage
Research, mechanism, dosing, and effectiveness of ARA-290 for nerve damage.
Quick Answer
ARA-290 is being studied for neuropathic pain and diabetic neuropathy.
Evidence Level
Phase II/III Trials
Typical Dose
Under clinical investigation
Results Timeline
Neuroprotective effects in trials
FDA Status
Research Only
How ARA-290 Works for Nerve Damage
Erythropoietin-derived peptide provides tissue protection without erythropoiesis.
About Nerve Damage
Support for nerve repair and regeneration.
Research Evidence
Phase II/III clinical trials for diabetic neuropathy show improvement in corneal nerve fiber density and small fiber function. Orphan Drug Designation granted in both US and EU for sarcoidosis treatment. Studies demonstrate efficacy in small fiber neuropathy, neuropathic pain, and sarcoidosis-related symptoms. Being developed by Araim Pharmaceuticals.
Dosing for Nerve Damage
Recommended Dose
Under clinical investigation
Frequency
Once daily
Administration
Subcutaneous injection
Duration
28-day courses in trials
Note: Cibinetide. Clinical trial doses. Used for neuropathy and sarcoidosis. Non-erythropoietic EPO derivative.
What to Expect
Initial adjustment period. Some users may notice subtle changes.
Early benefits often become noticeable. Continue consistent use.
Most users report meaningful improvements by this point.
Full effects typically realized. Reassess and adjust as needed.
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Generally well-tolerated in trials
- •Injection site reactions
- •No erythropoietic effects (no blood thickening)
- •Not FDA approved
Frequently Asked Questions
Does ARA-290 help with nerve damage?
ARA-290 is being studied for neuropathic pain and diabetic neuropathy.
How does ARA-290 work for nerve damage?
Erythropoietin-derived peptide provides tissue protection without erythropoiesis....
What dose of ARA-290 should I use for nerve damage?
Under clinical investigation
How long until I see results?
Neuroprotective effects in trials
Other Peptides for Nerve Damage
These peptides are also researched for nerve damage.
GB-115
Clinical TrialsA dipeptide anxiolytic and nootropic that acts as a CCK-1 (cholecystokinin) receptor antagonist. Developed in Russia with completed Phase 3 trials for anxiety. Users report significant improvements in focus, attention, and ADHD-like symptoms.
Selank
Clinical TrialsA synthetic peptide derived from tuftsin, an immunomodulatory peptide. Approved in Russia for anxiety and nootropic effects. Known for anxiolytic properties without sedation.
Semax
Clinical TrialsA synthetic peptide derived from ACTH (4-10) fragment with added Pro-Gly-Pro sequence. Approved in Russia for stroke and cognitive enhancement. Known for nootropic and neuroprotective effects.
Cerebrolysin
Clinical TrialsA mixture of low-molecular-weight neuropeptides derived from pig brain. Approved in many countries for stroke, traumatic brain injury, and dementia.
Educational Information Only
This information about ARA-290 for nerve damage is for educational purposes only. Always consult with qualified healthcare providers before using any peptide. Individual results may vary.